EGFR and cholangiocarcinoma: Other EGFR-targeted inhibitors were also used as alternative monotherapy and combination with cytotoxic agents therapy and developed for CCA also not improve survival in CCA patients in large clinical studies (Philip et al., 2006; Ramanathan et al., 2009; Gruenberger et al., 2010; Zhu et al., 2010).